Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with severe DILI (Drug Induced Liver Injury)~* Age more than or equal to 18 years~Exclusion Criteria:~* Patients with HAV (Hepatitis A Virus), HBV (Hepatitis B Virus), HCV (Hepatitis C Virus), HEV (Hepatitis E Virus) Positive~* Patients with sepsis~* AMA positive~* Low Ceruloplasmin~* Transferrin saturation \>45%~* Patients with Cirrhosis~* Patients with h/o jaundice prior to the intake of drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prednisolone + N-Acetylcysteine (Type: EXPERIMENTAL): Prednisolone for 20 days with NAC (N-Acetylcysteine) NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
- N-Acetylcysteine (Type: ACTIVE_COMPARATOR): NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h

Based on this trial design, predict the completion outcome and termination type (if applicable).